Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,516JPY
27 Apr 2017
Change (% chg)

¥-49 (-3.13%)
Prev Close
¥1,565
Open
¥1,558
Day's High
¥1,564
Day's Low
¥1,512
Volume
8,685,100
Avg. Vol
7,218,891
52-wk High
¥1,779
52-wk Low
¥1,415

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.59
Market Cap(Mil.): ¥3,370,733.00
Shares Outstanding(Mil.): 2,153.82
Dividend: 17.00
Yield (%): 2.11

Financials

  4503.T Industry Sector
P/E (TTM): 15.98 29.41 30.38
EPS (TTM): 97.93 -- --
ROI: 14.68 13.85 13.36
ROE: 15.78 14.79 14.50

BRIEF-Astellas Pharma to retire treasury shares

* Says it will retire 85 million shares( 4 percent of outstanding ) of its common stock on May 31

4:23am BST

BRIEF-Astellas Pharma to acquire Ogeda SA

* under agreement, Astellas has agreed to pay up to a total of eur 800 million

03 Apr 2017

BRIEF-RIBOMIC plans joint research agreement with Astellas pharma

* Says it plans to enter into joint research agreement with Astellas pharma Inc, regarding R&D of aptamers pharmaceuticals

21 Mar 2017

BRIEF-X-Chem signs broad drug discovery collaboration with Astellas Pharma

* X-Chem Inc - announced signing of a broad drug discovery collaboration with Astellas Pharma Inc

20 Mar 2017

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

28 Feb 2017

BRIEF-Lupin's unit Kyowa and Astellas enter into agreement

* Says Astellas and Lupin s subsidiary Kyowa enter into an agreement

27 Feb 2017

BRIEF-Astellas says to buy back up to 1.43 pct of own shares worth 50 bln yen

* to buy back up to 1.43 percent of own shares worth 50 billion yen Further company coverage:

31 Jan 2017

BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan

* Astellas and Ironwood report positive top-line results from phase III Linaclotide trial for patients with chronic constipation conducted in Japan

30 Jan 2017

Synergy wins U.S. approval for constipation drug (Jan 19)

(The Jan. 19 story corrects paragraph 9 to say Ironwood Pharma also sells Linzess in North America)

24 Jan 2017

More From Around the Web

Earnings vs. Estimates